Viral vectors for gene therapy
Molecular Medical Microbiology, Page: 2659-2679
2024
- 649Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures649
- Readers649
- 649
Book Chapter Description
This chapter provides a general background on viral vectors used for gene therapy applications and then more specifically focuses on the recent translational progress that has been made with adeno-associated virus (AAV) vectors. Viral vectors have emerged as powerful delivery tools for the enhancement, reduction, and restoration of gene expression. Retrovirus, lentivirus, adenovirus, herpes simplex virus, and AAV, have been used for ex vivo and in vivo gene transfer. The attributes and limitations of these vectors are discussed as well as their translational successes and failures. Due to its many recent clinical advances, the use of AAV in current clinical trials is listed and categorized by targeted organ (i.e., eye, liver, central nervous system, and others), and the predominant serotype capsids and administration routes utilized for each particular target organ are summarized. This chapter also covers AAV manufacturing, including contemporary platforms for large-scale vector production and quality control measures to ensure safety and efficacy.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/B9780128186190000198; http://dx.doi.org/10.1016/b978-0-12-818619-0.00019-8; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85184325685&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/B9780128186190000198; https://dx.doi.org/10.1016/b978-0-12-818619-0.00019-8
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know